ClinicalTrials.gg
Drug

Recombinant FVIIa clinical trials

Also written activated recombinant human factor VII and NovoSeven.

studies test it
58
open now
4
in phase 3
14
first study started
1998

How each study uses recombinant FVIIa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the recombinant FVIIa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Mar 1999 · Novoseven, Novoseven Rt · BLA 103665 (FDA, Purple Book)
European Union
23 Feb 1996 · NovoSeven · EMEA/H/C/000074 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

rFVIIa
3
Recombinant Factor VIIa
3
Recombinant Activated Factor VII (rFVIIa)
2

Brand

NovoSeven
5
NiaStase
1
SEVENFACT
1

Other names

activated recombinant human factor VII
29
eptacog alfa (activated)
11
Coagulation Factor VIIa (Recombinant)
4
recombinant activated factor VII
3

Studies by the year they started

57 studies that test it; most in 2005 (9)

Studies that test recombinant FVIIa, by start year
YearStudies
19981
20001
20018
20027
20045
20059
20064
20073
20082
20102
20112
20122
20131
20142
20161
20171
20212
20241
20253

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
24
Phase 3
14
Phase 4
6
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 41 · Other 17

Novo Nordisk A/S (36) · Joseph Broderick, MD (2) · Laboratoire français de Fractionnement et de Biotechnologies (2) · rEVO Biologics (2) · Sheba Medical Center (2) · AryoGen Pharmed Co. (1) · Dr. David Gladstone (1) · University of Cincinnati (1)

Often tested with

Tested in the same studies.

Vatreptacog alfa (2) · Factor VIII (1) · Biosimilar Pharmaceuticals (1) · Warfarin (1) · Anti-inhibitor coagulant complex (1) · Prothrombin complex concentrate (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test recombinant FVIIa.

Studies

Open first, then newest update. How each study uses recombinant FVIIa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 58

See all 58 studies that test recombinant FVIIa →

Given beside what is tested · 5 — recombinant FVIIa is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with recombinant FVIIa

Codes

What other systems call recombinant FVIIa · ClinicalTrials.gg INT003954

  • MeSH (NLM) C103587recombinant FVIIaOne source NLM
  • UNII (FDA) AC71R787OVCOAGULATION FACTOR VIIA RECOMBINANT HUMANConfirmed FDA, NLM
  • RxNorm 253149One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.